[{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"BCX9930","moa":"Complement Factor D","graph1":"Hematology","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"PLX-R18","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ Not Applicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"OMS906","moa":"MBL-associated serine protease","graph1":"Hematology","graph2":"Phase I","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Omeros \/ Not Applicable"},{"orgOrder":0,"company":"eXIthera Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"EP-7041","moa":"Factor XIa","graph1":"Hematology","graph2":"Phase I","graph3":"eXIthera Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"eXIthera Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"eXIthera Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"OMS906","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Omeros \/ Not Applicable"},{"orgOrder":0,"company":"Hillhurst Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Carbon Monoxide","moa":"HO metabolic pathway","graph1":"Hematology","graph2":"Phase I","graph3":"Hillhurst Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hillhurst Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hillhurst Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Veralox Therapeutics","sponsor":"Hatteras Venture","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2021","type":"Series A Financing","leadProduct":"VLX-1005","moa":"12-LOX","graph1":"Hematology","graph2":"Phase I","graph3":"Veralox Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Veralox Therapeutics \/ Hatteras Venture","highestDevelopmentStatusID":"6","companyTruncated":"Veralox Therapeutics \/ Hatteras Venture"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Desidustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Phase I","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"NM8074","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"NovelMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"NovelMed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NovelMed Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Not Applicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"KER-012","moa":"SMAD 2\/3","graph1":"Hematology","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Keros Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Not Applicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SCB-219M","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4","graph1":"Hematology","graph2":"Phase I","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"X4 Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Motixafortide","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioLineRx \/ Washington University School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"OMS906","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Omeros \/ Not Applicable"},{"orgOrder":0,"company":"Hillhurst Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Carbon Monoxide","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"Hillhurst Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Hillhurst Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hillhurst Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"STP122G","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Not Applicable"},{"orgOrder":0,"company":"Velico Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Plasma","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"Velico Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Velico Medical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Velico Medical \/ Not Applicable"},{"orgOrder":0,"company":"Hillhurst Biopharmaceuticals","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Carbon Monoxide","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"Hillhurst Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Hillhurst Biopharmaceuticals \/ National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"6","companyTruncated":"Hillhurst Biopharmaceuticals \/ National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"GMI-1687","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GlycoMimetics \/ Not Applicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"SCB-219M","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Motixafortide","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx \/ Not Applicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"St. Jude Children's Research Hospital","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"Motixafortide","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"BioLineRx \/ St. Jude Children's Research Hospital","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx \/ St. Jude Children's Research Hospital"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The collaboration aims to advance the novel anticoagulant ATI-5923 (tecarfarin), designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with implanted cardiac devices.

                          Brand Name : ATI-5923

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 06, 2024

                          Lead Product(s) : Tecarfarin

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase I

                          Sponsor : Abbott Laboratories

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : STP122G is a GalNAc-based RNAi therapeutic, SC formulation, targetting Factor XI. It is in early-stage development as an anticoagulant, utilizing company's proprietary GalAhead platform.

                          Brand Name : STP122G

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          July 08, 2024

                          Lead Product(s) : STP122G

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The agreement aims to evaluate motixafortide for the mobilization of CD34+ hematopoietic stem cells (HSCs) used in the development of gene therapies for patients with sickle cell disease (SCD).

                          Brand Name : Aphexda

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          May 30, 2024

                          Lead Product(s) : Motixafortide

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase I

                          Sponsor : St. Jude Children's Research Hospital

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : GMI-1687 is a highly potent E-selectin antagonist that is bioavailable after subcutaneous administration. It is under phase 1 clinical development for the treatment of sickle cell disease.

                          Brand Name : GMI-1687

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 04, 2024

                          Lead Product(s) : Uproleselan

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : SCB-219M is an innovative TPO-RA mimetic bispecific Fc-fusion protein produced from CHO cells. It is under phase 1 clinical development for the treatment of cancer patients with chemotherapy-induced thrombocytopenia.

                          Brand Name : SCB-219M

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          December 28, 2023

                          Lead Product(s) : SCB-219M

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : BioLineRx initiated Phase I clinical trial studies evaluating BL-8040 (motixafortide), CXCR4/SDF-1 inhibitor, as monotherapy and in combination with natalizumab for the treatment of sickle cell disease.

                          Brand Name : BL-8040

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          December 21, 2023

                          Lead Product(s) : Motixafortide,Natalizumab

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed